TradingViewTradingView

Key facts: Novo Nordisk is in talks with the Trump administration regarding the 'most-favoured-nation' order aimed at addressing drug price differences between the U.S. and other wealthy nations.

Moins d'1 minute de lecture
  • Novo Nordisk is in talks with the Trump administration regarding the 'most-favoured-nation' order aimed at addressing drug price differences between the U.S. and other wealthy nations.1
  • Novo Nordisk will provide its diabetes drug Ozempic for $499 monthly to eligible cash-paying U.S. patients with type 2 diabetes, partnering with telehealth service GoodRx.2
  • GoodRx has expanded its partnership with Kroger to improve savings on Novo Nordisk's Wegovy, enabling access to discounts at nearly 2,200 Kroger pharmacies nationwide.3